Buy Indoco Remedies; target of Rs 380: Prabhudas Lilladher
Prabhudas Lilladher is bullish on Indoco Remedies has recommended buy rating on the stock with a target price of Rs 380 in its research report dated July 25, 2023.27-07-2023
27-07-2023
INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Newspaper Publication
NEWSPAPER PUBLICATION OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30-06-202326-07-2023
INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, this is to inform you that the Company''s manufacturing facility for solid oral dosage form (Unit I) located at Baddi has received EU GMP Certification from Competent Health Authority of Malta confirming that the Facility complies with the Good Manufacturing Practice requirements as referred in the EC Directive. Please find enclosed press release in this regard.26-07-2023
INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to the Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, the audio recording of the earnings conference call in respect of Unaudited Standalone and Consolidated Financial Results for the Quarter ended 30th June, 2023 held today i.e. 25th July, 2023 at 03:30 p.m. (IST) is available on the Company's website at https://www.indoco.com/inv-fin-concall-transcripts.asp. The Earnings Conference Call concluded at 04:15 p.m. (IST) on 25th July, 2023.25-07-2023
Q1FY24 Quarterly Result Announced for Indoco Remedies Ltd.
Pharmaceuticals company Indoco Remedies announced Q1FY24 results: Revenues of Indoco Remedies grew by 5% at Rs 413.2 crore, as against Rs 394.9 crore in Q1FY23. EBIDTA to net sales for Q1FY24 is 15.2% at Rs 62.9 crore, compared to 18.1 % at Rs71.3 crore in Q1FY23. Profit After Tax is at Rs 25.7 crore, compared to Rs 37.5 crore in Q1FY23. Commenting on the results, Aditi Panandikar, Managing Director, Indoco Remedies said, “Our first quarter results demonstrate good growth in API business, complemented by steady performance in the Domestic Formulation business. We remain optimistic for the rest of the year and are committed to building and further strengthening our position in the market”. Result PDF25-07-2023
INDOCO REMEDIES LTD. - 532612 - Unaudited Standalone And Consolidated Financial Results For The Quarter Ended 30Th June, 2023
Pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, we attach herewith the Unaudited Standalone and Consolidated Financial Results for the Quarter ended 30th June, 202325-07-2023
INDOCO REMEDIES LTD. - 532612 - Board Meeting Outcome for Outcome Of Board Meeting Held On 25Th July, 2023
Pursuant to the Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 25th July, 2023 has inter-alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2023 along with the Limited Review Report with unmodified opinion on the aforesaid Unaudited Financial Results.25-07-2023
INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
This is to inform you that an Earnings Conference Call on Unaudited Financial Results for the quarter ended 30-06-2023 is scheduled to be held on 25-07-2023 at 03:30 pm IST.18-07-2023
INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
This is to inform you that an Earnings Conference Call on Unaudited Financial Results for the quarter ended 30-06-2023 is scheduled to be held on Tuesday, 25-07-2023 at 03:30 P.M. IST.18-07-2023
INDOCO REMEDIES LTD. - 532612 - Board Meeting Intimation for To Consider And Approve The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended 30Th June, 2023.
INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/07/2023 ,inter alia, to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter ended 30th June, 2023.14-07-2023